Header Logo

Connection

JULIE NANGIA to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications JULIE NANGIA has written about Breast Neoplasms.
JULIE NANGIA
Connection Strength
1.796
Breast Neoplasms
  1. Breast Cancer Prevention: Where Are We? JCO Oncol Pract. 2021 12; 17(12):720-722.
    View in: PubMed
    Score: 0.328
  2. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
    View in: PubMed
    Score: 0.238
  3. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501.
    View in: PubMed
    Score: 0.168
  4. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002.
    View in: PubMed
    Score: 0.099
  5. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
    View in: PubMed
    Score: 0.093
  6. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. 2022 12 12; 40(12):1521-1536.e7.
    View in: PubMed
    Score: 0.089
  7. Prognostic Impact of Radiation Therapy in Pure Mucinous Breast Carcinoma. Clin Breast Cancer. 2022 10; 22(7):e807-e817.
    View in: PubMed
    Score: 0.086
  8. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
    View in: PubMed
    Score: 0.086
  9. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.085
  10. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.072
  11. Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma. Breast J. 2020 04; 26(4):653-660.
    View in: PubMed
    Score: 0.071
  12. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
    View in: PubMed
    Score: 0.071
  13. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
    View in: PubMed
    Score: 0.070
  14. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
    View in: PubMed
    Score: 0.069
  15. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
    View in: PubMed
    Score: 0.065
  16. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prev Res (Phila). 2018 04; 11(4):203-214.
    View in: PubMed
    Score: 0.064
  17. Jejunal intussusception due to malignant phyllodes tumor of the breast. Clin Breast Cancer. 2012 Jun; 12(3):219-21.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.